



Dkt. 41426-C/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ron S. Israeli, et al.

Serial No.: 08/466,381

Filed : June 6, 1995

For : PROSTATE-SPECIFIC MEMBRANE ANTIGEN

Group Art Unit: 1645

Examiner: S. Gucker

1185 Avenue of the Americas
New York, New York 10036
December 12, 2002

Assistant Commissioner for Patents
U.S. Patent and Trademark Office, P.O. Box 2327
Arlington, VA 22202

Attn: Box Sequence

Sir:


STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(e) and submitted as **Exhibit C** in connection with the above-identified application, has the same information as the pages attached hereto as **Exhibit B**, and entitled "Sequence Listing."

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

David J. Kerwick
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



41426-1
UNITED STATES DEPARTMENT OF COMMERCE JPW
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
---------------	-------------	-----------------------	---------------------

10/22/2002
1 mo: 11/22/2002
2 mos: 12/22/2002
3 mos: 1/22/2003
4 mos: 2/22/2003
5 mos: 3/22/2003
6 mos: 4/22/2003 *sml*

OCT 28 2002

EXAMINER	
ART UNIT	PAPER NUMBER
35	

DATE MAILED:

Please find below a communication from the **EXAMINER** in charge of this application

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Gucker whose telephone number is (703) 308-6571. The examiner can normally be reached on Monday to Friday from 0930 to 1800. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623. The fax phone number for this Group is currently (703) 308-4242, but Applicant should confirm this by phoning the Examiner before faxing.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SG

Stephen Gucker

October 17, 2002

Gary L. Kunz
GARY KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

RECEIVED
DEC 30 2002
TECH CENTER 1600/2900



Application No.: 08/466,381

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:
- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



RECEIVED

AUG 12 2002

TECH CENTER 1600/2800



1600

RAW SEQUENCE LISTING

DATE: 08/06/2002

PATENT APPLICATION: US/08/466,381A

TIME: 17:12:26

Input Set : A:\EP.txt

Output Set: N:\CRF3\08062002\H466381A.raw

Does Not Comply
Corrected Diskette Needed

1 <110> APPLICANT: Israeli, Ron S. Heston,
-> 2 <120> TITLE OF INVENTION: PROSTATE-SPECIFIC MEMBRANE ANTIGEN<130>
-> 3 <140> CURRENT APPLICATION NUMBER: US 08/466,381<141> 1995-06-06<150> USA
-> 0 <130> FILE REFERENCE:
-> 4 <141> CURRENT FILING DATE: 1995-06-06
-> 4 <151> PRIOR FILING DATE: 1995-03-17<160> 38 <170> PatentIn version 3.1<210> 1<211>

RORED SEQUENCES

5 <212> TYPE: DNA<213> Human<400> 1
-> 6 <210> SEQ ID NO:
-> 6 <211> LENGTH:
-> 6 <213> ORGANISM:
-> 6 <400> SEQUENCE:

6 ctcaaaagg ggcggatttc cttctcctgg aggcagatgt tgcctctctc tctcgctcgg 60
8 attggttcag tgcactctag aaacactgct gtggtggaga aactggaccc caggtctgga 120
10 gcgaattcca gcctgcaggg ctgataagcg aggcattagt gagattgaga gagactttac 180
12 cccgcgctgg tggttgagg gcgcgcagta gacgagcagc acaggcgcggt gtcccgaggag 240
14 cccggtctct ctgcgcgcca gatgtggaat ctcccttcacg aaaccgactc ggctgtggcc 300
16 accgcgcgcc gccgcgctg gctgtgcgct ggggcgctgg tgcgtggcggg tggcttcttt 360
18 ctccctcggt tccctcttcgg gtggtttata aaatcctcca atgaagctac taacattact 420
20 ccaaagcata atatgaaagc atttttggat gaattgaaag ctgagaacat caagaagttc 480
22 ttatataatt ttacacagat accacattta gcaggaacag aacaaaactt tcagcttgca 540
24 aagcaaattc aatcccagtg gaaagaattt ggccctggatt ctggtgagct agcacattat 600
26 gatgtcctgt tgtcctaccc aaataagact catcccaact acatctcaat aattaatgaa 660
28 gatggaaatg agattttcaa cacatcatta ttggaaccac ctccctccagg atatgaaaat 720
30 gtttcggata ttgtaccacc tttcagtgtc ttctctctc aaggaatgcc agaggcgat 780
32 ctagtgtatg ttaactatgc acgaactgaa gacttcttta aattggaacg ggacatgaaa 840
34 atcaatttgt ctgggaaaaat tgtaattgcc agatatggga aagttttcag aggaaataag 900
36 gttaaaaatg ccagctggc aggggcccac ggagtcattc tctactccga ccctgctgac 960
38 tactttgtct ctggggtgaa gtccctatcca gatggttgga atcttctctg aggtggtgtc 1020
40 cagcgtggaa atactcctaaa tctgaatggg gcaggagacc ctctcacacc aggttaccca 1080
42 gcaaatgaat atgcttatag gcgtggaatt gcagaggctg ttggtcttcc aagtattcct 1140
44 gttcatccaa ttggatacta tgatgcacag aagctcctag aaaaaatggg tggctcagca 1200
46 ccaccagata gcagctggag aggaagtctc aaagtgcctt acaatgttgg acctggcttt 1260
48 actggaactc ttctacaca aaaagtcaag atgcacatcc actctaccaa tgaagtgaac 1320
50 agaatttaca atgtgatagg tactctcaga ggagcagtg aaccagacag atatgtcatt 1380
52 ctggggaggt accgggactc atgggtgttt ggtggtattg accctcagag tggagcagct 1440
54 gttgttcatt aaattgtgag gagcttttga acactgaaaa aggaagggtg gagacctaga 1500
56 agaacaattt tgtttgcaag ctgggatgca gaagaatttg gtcttcttgg ttctactgag 1560
58 tgggcagagg agaattcaag actccttcaa gagcgtggcg tggcttatat taatgctgac 1620
60 tcatctatag aaggaaacta cactctgaga gttgattgta caccgctgat gtacagcttg 1680

sample of submitted file - global
format
error

Please
contact
Robert Wax
at

703-306-4119

or
703-308-4216

for
assistance